ucsf
(2)
Therini Bio, Inc.
Therini Bio is a clinical-stage biotechnology company developing fibrin-targeting immunotherapies for neurodegenerative and retinal diseases driven by vascular dysfunction. Founded in 2019 on the neurovascular research of Dr. Katerina Akassoglou at UCSF and the Gladstone Institutes, the company's lead antibody THN391 selectively blocks fibrin's inflammatory epitope to halt chronic neuroinflammation without interfering with normal blood clotting. Backed by roughly $145M in total funding from investors including Eli Lilly, Sanofi Ventures, Merck's MRL Ventures and the Dementia Discovery Fund, Therini is advancing THN391 into Phase 1b trials for Alzheimer's disease and diabetic macular edema.
Voio
Voio is a Berkeley-based frontier AI lab building a unified reading platform for radiology. Spun out of UC Berkeley and UCSF, it develops the open-source Pillar family of models that interpret CT, MRI and X-ray scans across hundreds of conditions, aiming to help radiologists work faster without trading away accuracy. The company exited stealth in November 2025 with $8.6M in seed funding.